Superworth

Century Therapeutics price to book ratio IPSC

Market value divided by the book value of the company's net assets, since 2021.

Today, Nov 2, 2026
1.2×
5-year median
1.0×
Against its 5-year history
55th
percentile: 0 is its lowest day, 100 its highest
5-year range
0.2× to 3.9×
Peer median
4.9×

Century Therapeutics' price to book ratio is 1.2× as of Nov 2, 2026.

That is above its 5-year median of 1.0×, close to the middle of its last 5 years.

Over that time it ranged from 0.2× in Aug 2025 to 3.9× in Aug 2021.

The median for 4 biotech stocks of a similar size is 4.9×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far1.2×0.5×2.9×
20250.5×0.2×0.5×
20240.5×0.5×1.8×
20230.9×0.3×0.9×
20220.9×0.9×2.0×
20212.0×1.9×3.9×

Against its peers

Companies in Biotechnology nearest Century Therapeutics' size, closest first, today.

CompanyPrice to book ratio
IPSCCentury Therapeutics1.2×
PLXProtalix BioTherapeutics2.9×
MGTXMeiraGTx4.2×
VCELVericel5.6×
ADMAAdma Biologics6.1×
Peer median4.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Century Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.